These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 19839930)

  • 1. Role of pemetrexed and platinums combination in patients with non-small cell lung cancer.
    Chen M; Shao W; He J; Wang D
    Curr Drug Targets; 2010 Jan; 11(1):29-36. PubMed ID: 19839930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of pemetrexed combined with targeted agents for non-small cell lung cancer.
    Konopa K; Jassem J
    Curr Drug Targets; 2010 Jan; 11(1):2-11. PubMed ID: 19839932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.
    Kim ES; Neubauer M; Cohn A; Schwartzberg L; Garbo L; Caton J; Robert F; Reynolds C; Katz T; Chittoor S; Simms L; Saxman S
    Lancet Oncol; 2013 Dec; 14(13):1326-36. PubMed ID: 24231627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer.
    Li T; Lara PN; Mack PC; Perez-Soler R; Gandara DR
    Curr Drug Targets; 2010 Jan; 11(1):85-94. PubMed ID: 19839922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease.
    Choi MK; Hong JY; Chang W; Kim M; Kim S; Jung HA; Lee SJ; Park S; Chung MP; Sun JM; Park K; Ahn MJ; Ahn JS
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1217-25. PubMed ID: 24696125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemetrexed in advanced non-small cell lung cancer.
    Gridelli C; Maione P; Rossi A; Bareschino MA; Schettino C; Sacco PC; Zeppa R
    Expert Opin Drug Saf; 2011 Mar; 10(2):311-7. PubMed ID: 21261558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pemetrexed in the treatment of non-small cell lung cancer.
    Shepherd FA
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):43-8. PubMed ID: 12571810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed plus carboplatin or oxaliplatin in advanced non-small cell lung cancer.
    Scagliotti GV
    Semin Oncol; 2005 Apr; 32(2 Suppl 2):S5-8. PubMed ID: 15818537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolving role of pemetrexed (Alimta) in lung cancer.
    Socinski MA; Stinchcombe TE; Hayes DN
    Semin Oncol; 2005 Apr; 32(2 Suppl 2):S16-22. PubMed ID: 15818533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC).
    Wagner TD; Yang GY
    Curr Drug Targets; 2010 Jan; 11(1):67-73. PubMed ID: 19839925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed for treatment of advanced non-small cell lung cancer.
    Fossella FV
    Semin Oncol; 2004 Feb; 31(1 Suppl 1):100-5. PubMed ID: 14981587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action.
    Joerger M; Omlin A; Cerny T; Früh M
    Curr Drug Targets; 2010 Jan; 11(1):37-47. PubMed ID: 19839929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seeking new options for the treatment of small-cell lung cancer.
    Socinski MA
    Lung Cancer; 2005 Oct; 50 Suppl 1():S25-6. PubMed ID: 16291430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pemetrexed: potential role in the adjuvant chemotherapy of non-small cell lung cancer.
    Vincent M
    Curr Drug Targets; 2010 Jan; 11(1):78-84. PubMed ID: 19839923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
    Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
    Paz-Ares LG; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    J Clin Oncol; 2013 Aug; 31(23):2895-902. PubMed ID: 23835707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs.
    Prescrire Int; 2009 Jun; 18(101):114. PubMed ID: 19637425
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC).
    Giovannetti E; Honeywell R; Hanauske AR; Tekle C; Kuenen B; Sigmond J; Giaccone G; Peters GJ
    Curr Drug Targets; 2010 Jan; 11(1):12-28. PubMed ID: 19839931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.
    Doebele RC; Spigel D; Tehfe M; Thomas S; Reck M; Verma S; Eakle J; Bustin F; Goldschmidt J; Cao D; Alexandris E; Yurasov S; Camidge DR; Bonomi P
    Cancer; 2015 Mar; 121(6):883-92. PubMed ID: 25377507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.
    Kim YH; Hirabayashi M; Kosaka S; Nikaidoh J; Yamamoto Y; Shimada M; Toyazaki T; Nagai H; Sakamori Y; Mishima M
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1445-51. PubMed ID: 23532206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.